美国CDC更新指南:无并发症恶性疟青蒿琥酯-苯芴醇疗程延长至5天
美国CDC基于疟疾监测数据、临床咨询记录、抗疟药分子耐药监测及文献荟萃分析,评估旅客中青蒿琥酯-苯芴醇(AL)治疗失败风险。据此更新指南,推荐美国无并发症恶性疟采用5天(10剂)AL延长疗程。
要点
- 美国无并发症恶性疟推荐AL 5天(10剂)延长疗程。
- AL失败多为初治后1-8周的晚期再燃,占85%。
- 延长AL疗程耐受良好,lumefantrine暴露更高。
核心结论
- 美国CDC更新指南,推荐无并发症恶性疟用5天(10剂)AL疗程。
研究设计与样本
- 综述美国CDC疟疾监测数据、临床咨询记录和抗疟药分子耐药监测数据,并开展文献综述与荟萃分析。
主要发现
- AL治疗失败中85%为初治后1-8周出现的晚期再燃。
- 延长AL疗程尤其是5天(10剂)方案耐受良好,并持续获得更高的lumefantrine暴露。
关键数值与推荐
- 美国CDC推荐无并发症恶性疟采用5天(10剂)AL延长疗程。
临床怎么用
- 在美国诊治无并发症恶性疟时,应按更新后的CDC指南选用5天(10剂)AL疗程,而非标准3天疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemisinin-based combination therapies (ACTs) are recommended for treatment of uncomplicated Plasmodium falciparum malaria; artemether-lumefantrine (AL) is the only ACT available in the United States. Reports of AL treatment failure among international travelers raise concerns about the continued adequacy of the standard 3-day AL regimen for travelers. METHODS: We reviewed US malaria surveillance data, clinical consultation records, and antimalarial molecular resistance surveillance data at the Centers for Disease Control and Prevention (CDC). We also conducted a literature review and meta-analysis to assess the risk of treatment failure following treatment with AL or atovaquone-proguanil (AP) in travelers treated in nonendemic settings and reviewed the efficacy and safety of AL regimens with durations longer than the standard 3-day (6-dose) course. RESULTS: From November 2022 through October 2025, CDC was consulted on 47 P. falciparum treatment failures, including 40 following AL-based and 7 following AP-based treatments. All reported travel to Africa, and 62% presented with severe malaria. Among AL failures, 85% were late recrudescences occurring 1-8 weeks after initial treatment. In the meta-analysis, the pooled AL treatment failure risk was higher for data collected in 2018 or later (7% [95% CI, 1%-32%]) compared to before 2018 (4% [95% CI, 2%-8%]), although the difference was not statistically significant (P = .3). Extended AL regimens, particularly a 5-day (10-dose) course, were well tolerated and consistently achieved higher lumefantrine exposure. CONCLUSIONS: These findings informed updated CDC guidance recommending an extended 5-day (10-dose) course of AL for treating uncomplicated P. falciparum malaria in the United States.
引用
- Hwang J, Halsey ES, Plucinski MM, et al. Extending the Duration of Artemether-Lumefantrine Treatment for Uncomplicated Plasmodium falciparum Malaria: Updated US Centers for Disease Control and Prevention Guidance Based on Review of Surveillance, Consultations, and Published Data. Clin Infect Dis. 2026. PMID: 42616037. doi:10.1093/cid/ciag456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。